Here’s what you need to know:
1. PixarBio advertises NeuroRelease as a “non-addictive and non-opiate treatment of pain,” meant to replace morphine usage in surgical patients.
2. NeuroRelease affects a patient’s sensory signals, rather than locomotion nerve fibers, to facilitate quick transition to physical therapy.
3. The company hopes to receive FDA approval for their 14-day postoperative pain treatment in 2018. The company also plans to offer four to eight hour, three day, seven day and 90 day pain treatments.
More articles on anesthesia:
White House promotes initiatives for Prescription Opioid and Heroin Epidemic Awareness Week: 5 notes
AANA stands in support of Prescription Opioid and Heroin Epidemic Awareness Week: 3 notes
NorthStar Anesthesia selects new EMR solution: 3 notes on Anesthesia Touch
